0001209191-21-016029.txt : 20210302
0001209191-21-016029.hdr.sgml : 20210302
20210302163627
ACCESSION NUMBER: 0001209191-21-016029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210226
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kilroy Conor
CENTRAL INDEX KEY: 0001808510
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 21704291
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-26
1
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001808510
Kilroy Conor
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
0
1
0
0
SVP, GC & Secretary
Class A Common Stock
2021-02-26
4
S
0
1399
9.11
D
127926
D
Class A Common Stock
2021-02-26
4
S
0
1474
9.11
D
126452
D
Class A Common Stock
2021-02-26
4
S
0
2268
9.11
D
124184
D
Class A Common Stock
2021-02-26
4
S
0
1848
9.11
D
122336
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February
27, 2017.
The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January
29, 2019.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
/s/ Brian Tessler, Attorney-in-Fact
2021-03-02